Dr. Gregory M. Fox, M.D.
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Medical school
- University of Michigan Medical School (1987)
- Years since graduation
- 39
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,283
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1987Medical school: University of Michigan Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
KS license 04-27847 · MI license 4301051175 · MO license 116603 -
Retina Specialist (Ophthalmology) Physician
KS license 116603 · MI license 4301051175 · MO license 0427847
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Adventhealth Shawnee Mission Shawnee Mission, KS
Medical groups
- Retina Associates LLC (12 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,283
- Services billed
- 43,814
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 11,940 | 42 |
| Injection, aflibercept, 1 mg | 3,901 | 340 |
| Imaging of retina | 3,331 | 1,010 |
| Injection of drug into eye | 2,516 | 526 |
| Injection, ranibizumab, 0.1 mg | 1,901 | 72 |
| Established patient complete exam of visual system | 929 | 668 |
| Photography of the retina | 550 | 462 |
| Unclassified biologics | 348 | 109 |
| Established patient office or other outpatient visit, 30-39 minutes | 319 | 250 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 249 | 239 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Lenexa, KS | 230 |
| Ketorolac Tromethamine Other prescribers in Lenexa, KS | 106 |
| Moxifloxacin (moxifloxacin hcl) Other prescribers in Lenexa, KS | 92 |
| Timolol Maleate Other prescribers in Lenexa, KS | 82 |
| Latanoprost Other prescribers in Lenexa, KS | 66 |
| Brimonidine Tartrate-Timolol (brimonidine tartrate/timolol) Other prescribers in Lenexa, KS | 42 |
| Prolensa (bromfenac sodium) | 39 |
| Brimonidine Tartrate Other prescribers in Lenexa, KS | 37 |
| Dorzolamide Hcl Other prescribers in Lenexa, KS | 35 |
| Ofloxacin Other prescribers in Lenexa, KS | 23 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 18 payments worth $584 in total to this clinician.
| Apellis Pharmaceuticals, Inc. | $218 |
|---|---|
| AbbVie Inc. | $74.00 |
| Regeneron Healthcare Solutions, Inc. | $73.54 |
| Ani Pharmaceuticals, Inc. | $73.54 |
| Neurotech Pharmaceuticals, Inc. | $66.15 |
| Carl Zeiss Meditec USA, Inc. | $41.16 |
| Genentech USA, Inc. | $23.20 |
| Astellas Pharma US Inc | $15.07 |
| Food and Beverage | $584 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $24,770 in research payments for these studies, mostly to the institutions running them.
- OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF FARICIMAB in PATIENTS WITH nAMD
Genentech, Inc. - BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
Bayer HealthCare Pharmaceuticals Inc. - VA2 PhIII Yosemite
Genentech, Inc. - Faricimab DME Long Term Extension Rhone X
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.